Interventional trials targeting MetS through lifestyle modifications, pharmacological agents (e.g., metformin, glucagon-like peptide 1 (GLP-1) agonists, anti-inflammatory drugs), or antioxidant therapy could assess their impact on ocular health, evaluating outcomes through retinal imaging, intraocular pressure, and tear film stability. The gene discussed is GCG; the disease is metabolic syndrome.